In Brief: Jacobio/AZ’s JAB-23E73 Reports First Clinical Results For Pan-KRAS Inhibitors

 
• By Dexter Jie Yan
  
Pancreatic ductal adenocarcinoma is a major target indication for JAB-23E73. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D